-
Upside Of 124% Expected For Akebia Therapeutics Following Vadadustat Collaboration
Wednesday, April 26, 2017 - 10:10am | 308Read More...Analysts at JMP Securities believe Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that develops therapeutics based on hypoxia-inducible factor (HIF) biology, could deliver investors a triple-digit percentage return. JMP's Michael King maintains an Outperform rating on Akebia's...
-
Akebia Therapeutics Lower Following Announcement Of Public Offering, Corporate And Clinical Developments
Tuesday, January 5, 2016 - 10:03am | 297Read More...Shares of Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that focuses on products for the treatment of kidney diseases, were trading lower by around 0.5 percent early Tuesday morning after the company announced it plans on offering and selling $75 million worth of its...
